Sector Update: Health Care Stocks Decline Late Afternoon

MT NewswiresDec 20 04:56

Immix Biopharma Announces Initial Data From First Four Patients In NEXICART-2 US Study; Says All Four Patients Treated With NXC-201 Normalized Disease Markers Within 30 Days Of Dosing, Of Which, Two Are Already Classified As Complete

BenzingaDec 19 22:36

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of Sterically-optimized CAR-T NXC-201 in Relapsed/refractory Light Chain (AL) Amyloidosis

GlobeNewswireDec 19 22:35

Immix Biopharma Publishes NXC-201 Clinical Results In Journal Of Clinical Oncology

BenzingaDec 16 22:51

Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

MT NewswiresDec 11 00:09

Immix Biopharma Announces 75% Complete Response Rate (N=16); 31.5 Months Best Response Duration (Ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

GlobeNewswireDec 10 22:39